Collegium Pharmaceutical Inc. (NASDAQ:COLL) changes shares on Tuesday trading session, with a change of 0.06% or $0.01 shares. The trading starts at $16.87 and closed at $16.65 throughout the day. The trading session low price was $16.14 and day high was $16.87 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.28 million while its average volume is 423.90K. In other hand, the COLL market cap reached to $588.43M.
On March 16, 2020, BRIEF-Collegium Pharmaceutical Files Prospectus For Sale By Assertio Therapeutics Of Up To 1 Mln Shares. According to the news reported on Reuters, * COLLEGIUM PHARMACEUTICAL INC – FILES PROSPECTUS RELATED TO OFFER & SALE BY ASSERTIO THERAPEUTICS OF UP TO 1 MILLION SHARES Source text: (http://www.sec.gov/archives/edgar/data/1267565/000104746920001528/0001047469-20-001528-index.htm ) Further company coverage:
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 1.22% and down -5.02% for month. Its quarterly performance was -10.38% below, while its half year performance is down -19.56%. COLL yearly performance stood at positive 58.67% and fall -19.05% for year-to-date. Current recommendation for Collegium Pharmaceutical Inc. is 2.10.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. COLL EPS (TTM) for 12-month is -0.38. EPS for this year is 42.80%, while for the next year its value is 1.70. Its EPS Q/Q reached 104.40%. It has an EPS of 5.70% up for past five years and for the next five years will be up 0.55%.
Let’s take a look on the analyst recommendations on COLL for the current month and previous month. For the current month, 8 of 10 analysts recommend stock as Buy while 1 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $8.00 – $38.00. Average target price for COLL was reached at $28.43.
Janus Henderson Group PLC, Blackrock Inc. and Eventide Asset Management LLC are the top three holders in Collegium Pharmaceutical Inc. (COLL) stock. On Mar 30, 2020, Janus Henderson Group PLC has 5.1 million shares which valued 83.35 million. On Mar 30, 2020, Blackrock Inc. owned 2.5 million shares which valued at 40.78 million. On Mar 30, 2020, Eventide Asset Management LLC has a total of 2.43 million shares which valued at 39.65 million. In the end, Eventide Asset Management LLC have 7.07% shares outstanding of Collegium Pharmaceutical Inc. (COLL) on Mar 30, 2020. The insider ownership moved to 2.40%.
The company posted an EPS (TTM) of -0.38. According to the most recent quarter report on (Jun 2020), 5 analysts estimated an average EPS of 0.2, while -0.14 EPS posted a year ago period. Analyst Estimated EPS for COLL published in the report was $0.03 – $0.29 during the same period. Comparing with last year, the average estimated EPS was -0.14 which is lower than 0.01 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for COLL fall -13.02% for period of 200 days. SMA for 50 days was -8.49% which is showing red signal, while SMA-20 was -1.24%. The moving average value for Collegium Pharmaceutical Inc. (COLL) is 5.02M and 12.67% for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in COLL stock. On Jul 13, Dreyer Scott, EVP & Chief Commercial Officer, sold 1,429 trading shares at the cost of $17.01, which valued at 24307.0. On Jun 02, Ciaffoni Joseph, President and CEO, sold 5,861 shares at the cost of $20.48, with total shares of 192,798. On Jun 01, Ciaffoni Joseph, President and CEO, sold 70,676 shares at the cost of 21.53. After this transaction, Ciaffoni Joseph total shares reached to 198,659 which valued at 1.52 million.